Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study

Hermine Raissa Hell; Maxwell Nguedjo Wandji; Celine Sylvie Mimboe Bilongo; Ruth Edwige Dibacto Kemadjou; Boris Ronald Tchuente Tonou; Therese Henriette Dimodi; Gabriel Medoua Nama; Olga Yvonne Mankollo Bassong

doi:doi:10.11648/j.cajph.20200606.18

Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study

Hermine Raissa Hell, Maxwell Nguedjo Wandji, Celine Sylvie Mimboe Bilongo, Ruth Edwige Dibacto Kemadjou, Boris Ronald Tchuente Tonou, Therese Henriette Dimodi, Gabriel Medoua Nama, Olga Yvonne Mankollo Bassong

Published in Central African Journal of Public Health (Volume 6, Issue 6)

Received: 13 October 2020 Accepted: 23 December 2020 Published: 31 December 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Diabetes is a public health problem worldwide and in sub-Saharan African countries such as Cameroon. According to many studies, the use of antipsychotic drugs increases the risk of developing diabetes mellitus by 2 to 3 times more in people with psychotic disorders than in the general population. The present study aimed to assess the influence of antipsychotic drugs used on the risk of developing diabetes and to identify other factors predictive of abnormal blood glucose levels in patients suffering from psychosis. Methods: A cross-sectional study was conducted from the 3rd to the 19th of January 2018. Patients aged at least 18 years old suffering from psychosis and undiagnosed as diabetic before initiation of antipsychotic treatment were recruited at the Jamot Hospital in Yaoundé. A questionnaire was used to collect sociodemographic, anthropometric, and clinical data. The Chi-Square test was used to assess the relationship between hyperglycemia and categorical variables and the multivariate logistic regression model was used to determine independent predictors of hyperglycemia through the Statistical Package for the Social Sciences (SPSS) version 20.0. Results: A total of 82 patients were included in the study (41 males and 41 females). The fasting blood sugar ≥100 mg/dL appeared to be higher but not significant in patients on atypical antipsychotic therapy (124.74±23.31mg/dL) compared to patients on typical antipsychotic therapy (115.74±18.63 mg/dL); with a positive and non-significant correlation between hyperglycemia and duration of treatment (r=0.215; p=0.053). However, in both typical and atypical antipsychotic patients, fasting glucose sugar levels between 110-125mg/dL were observed at the same level (118.07±4.84 mg/dL and 118.09±3.41mg/dL respectively). Male sex (OR=1.41; 95% CI 0.54-3.64), age group < 35 years (OR=1.84; 95% CI 0.69-4.88), single (OR=2.18; 95% CI 0.83-5.67), typical antipsychotic drugs (OR=1.12; 95% CI 0.42-3.01), schizophrenia (OR=1.80; 95% CI 0.25-12.84) and bipolar disorder (OR=1.50; 95% CI 0.14-15.46) were independent predictors of hyperglycemia in those patients. Conclusion: Regular monitoring of anthropometric and clinical parameters should be assigned to people suffering from psychotic disorders and under treatment. Therefore, they should benefit from good management of the risk factors for diabetes to prevent the onset of the disease and avoid increased morbidity and mortality in this vulnerable population.

Published in	Central African Journal of Public Health (Volume 6, Issue 6)
DOI	10.11648/j.cajph.20200606.18
Page(s)	365-371
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Risk Factors, Diabetes, Psychosis, Antipsychotic, Duration of Treatment

References

[1]	Maulik N, Reenu S, Rita M. (2016). Assessment of Oxidative Stress and Lipid Status in Patients of Type 2 Diabetes Mellitus with and without Complications. Int J Biochem Res Rev. 13 (1): 1-10.
[2]	Takuisssu NGR, Ngondi JL, Oben JE. (2020). Antioxidant and Glucose Lowering Effects of Hydroethanolic Extract of Baillonella toxisperma Pulp. J Food Res. 9 (2): 20-29.
[3]	International Diabetes Federation. (2019). Diabetes Atlas, 9éme edition.
[4]	Saeedi P, Petersohn I, Salpea P, et al. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 157: 1-10.
[5]	Domino EM, Swartz SM. (2008). Who Are the New Users of Antipsychotic Medications? Psychiatr Serv. 59 (5): 507-514.
[6]	Moreno-Kustner B, Martın C, Pastor L. (2018). Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS ONE. 13 (4): e0195687.
[7]	Jongsma HE, Turner C, Kirkbride JB, Jones PB. (2019). International incidence of psychotic disorders, 2002–17: a systematic review and meta-analysis. The Lancet Public Health. 4 (5): e229–e244.
[8]	Holt RIG. (2019). Association between Antipsychotic Medication Use and Diabetes. Curr Diab Rep. 19: 96.
[9]	Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. (2010). Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 197: 266-271.
[10]	Robinson DJ, Coons M, Haensel H, Vallis M, Yale J-F. (2018). Diabetes and Mental Health. Can J Diabetes. 42: S130-S141.
[11]	Saravane D. (2014). Metabolic complications of psychotropic drugs. PSN. 2 (12): 51-63.
[12]	International Diabetes Federation. (2005). The IDF consensus worldwide definition of the metabolic syndrome. 1-7.
[13]	Alberti KG, Zimmet PZ. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15 (7): 539-553.
[14]	World Health Organization. (2003). Diet, nutrition and the prevention of chronic diseases. Technical Reports Series, No. 916. World Health Organization, Geneva.
[15]	Liberty FI, Todder D, Umansky R, Harman-Boehm I. (2004). Atypical Antipsychotics and Diabetes Mellitus: An Association. IMAJ. 6: 276-279.
[16]	Wani RA, Dar MA, Margoob MA, Rather YH, Haq I, Shah MS. (2015). Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 6 (1): 17-22.
[17]	El Sheikh MW, Rajab ZA, Shalaby SA, Shaheen GA. (2019). Comparison between typical and atypical antipsychotics according their effects on metabolism in schizophrenia patients. Menoufia Med J. 32: 80-87.
[18]	Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. (2004). A Prospective Study of Impairment in Glucose Control Caused by Clozapine without Changes in Insulin Resistance. Am J Psychiatry. 161 (2): 361-363.
[19]	Gupte AA, Pownall HJ, Hamilton DJ. (2015). Estrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function. J Diabetes Res. 1-9.
[20]	Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC. (2006). Hyperglycemia and Diabetes in Patients with Schizophrenia or Schizoaffective Disorders. Diabetes Care. 29 (4): 786–791.
[21]	Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. (2008). Antipsychotics and Diabetes: An Age-Related Association. Ann Pharmacother. 42 (9): 1316-1322.
[22]	Zafar H, Zohra KN, Jawed AD, Iqbal A. (2011). Hyperglycemia and treatment with antipsychotics a study from a tertiary care centre. JPPS. 8 (2): 69-73.
[23]	Lipscombe LL, Lévesque LE, Gruneir A, et al. (2011). Antipsychotic Drugs and the Risk of Hyperglycemia in Older Adults without Diabetes: A Population-Based Observational Study. Am J Geriat Psychiat. 19 (12): 1026-1033.
[24]	Holt RIG, Peveler RC. (2009). Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 11: 665-679.
[25]	Correll CU, Lencz T, Malhotra AK. (2011). Antipsychotic drugs and obesity. Trends Mol Med. 17 (2): 97-107.
[26]	Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva V. (2017). Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsych Dis Treat. 13: 2231-2241.
[27]	Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. (2016). Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 15 (2): 166-174.

Cite This Article

Plain Text BibTeX RIS

APA Style

Hermine Raissa Hell, Maxwell Nguedjo Wandji, Celine Sylvie Mimboe Bilongo, Ruth Edwige Dibacto Kemadjou, Boris Ronald Tchuente Tonou, et al. (2020). Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Central African Journal of Public Health, 6(6), 365-371. https://doi.org/10.11648/j.cajph.20200606.18

Copy | Download

ACS Style

Hermine Raissa Hell; Maxwell Nguedjo Wandji; Celine Sylvie Mimboe Bilongo; Ruth Edwige Dibacto Kemadjou; Boris Ronald Tchuente Tonou, et al. Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Cent. Afr. J. Public Health 2020, 6(6), 365-371. doi: 10.11648/j.cajph.20200606.18

Copy | Download

AMA Style

Hermine Raissa Hell, Maxwell Nguedjo Wandji, Celine Sylvie Mimboe Bilongo, Ruth Edwige Dibacto Kemadjou, Boris Ronald Tchuente Tonou, et al. Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Cent Afr J Public Health. 2020;6(6):365-371. doi: 10.11648/j.cajph.20200606.18

Copy | Download

@article{10.11648/j.cajph.20200606.18,
  author = {Hermine Raissa Hell and Maxwell Nguedjo Wandji and Celine Sylvie Mimboe Bilongo and Ruth Edwige Dibacto Kemadjou and Boris Ronald Tchuente Tonou and Therese Henriette Dimodi and Gabriel Medoua Nama and Olga Yvonne Mankollo Bassong},
  title = {Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study},
  journal = {Central African Journal of Public Health},
  volume = {6},
  number = {6},
  pages = {365-371},
  doi = {10.11648/j.cajph.20200606.18},
  url = {https://doi.org/10.11648/j.cajph.20200606.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20200606.18},
  abstract = {Background: Diabetes is a public health problem worldwide and in sub-Saharan African countries such as Cameroon. According to many studies, the use of antipsychotic drugs increases the risk of developing diabetes mellitus by 2 to 3 times more in people with psychotic disorders than in the general population. The present study aimed to assess the influence of antipsychotic drugs used on the risk of developing diabetes and to identify other factors predictive of abnormal blood glucose levels in patients suffering from psychosis. Methods: A cross-sectional study was conducted from the 3rd to the 19th of January 2018. Patients aged at least 18 years old suffering from psychosis and undiagnosed as diabetic before initiation of antipsychotic treatment were recruited at the Jamot Hospital in Yaoundé. A questionnaire was used to collect sociodemographic, anthropometric, and clinical data. The Chi-Square test was used to assess the relationship between hyperglycemia and categorical variables and the multivariate logistic regression model was used to determine independent predictors of hyperglycemia through the Statistical Package for the Social Sciences (SPSS) version 20.0. Results: A total of 82 patients were included in the study (41 males and 41 females). The fasting blood sugar ≥100 mg/dL appeared to be higher but not significant in patients on atypical antipsychotic therapy (124.74±23.31mg/dL) compared to patients on typical antipsychotic therapy (115.74±18.63 mg/dL); with a positive and non-significant correlation between hyperglycemia and duration of treatment (r=0.215; p=0.053). However, in both typical and atypical antipsychotic patients, fasting glucose sugar levels between 110-125mg/dL were observed at the same level (118.07±4.84 mg/dL and 118.09±3.41mg/dL respectively). Male sex (OR=1.41; 95% CI 0.54-3.64), age group < 35 years (OR=1.84; 95% CI 0.69-4.88), single (OR=2.18; 95% CI 0.83-5.67), typical antipsychotic drugs (OR=1.12; 95% CI 0.42-3.01), schizophrenia (OR=1.80; 95% CI 0.25-12.84) and bipolar disorder (OR=1.50; 95% CI 0.14-15.46) were independent predictors of hyperglycemia in those patients. Conclusion: Regular monitoring of anthropometric and clinical parameters should be assigned to people suffering from psychotic disorders and under treatment. Therefore, they should benefit from good management of the risk factors for diabetes to prevent the onset of the disease and avoid increased morbidity and mortality in this vulnerable population.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study
AU  - Hermine Raissa Hell
AU  - Maxwell Nguedjo Wandji
AU  - Celine Sylvie Mimboe Bilongo
AU  - Ruth Edwige Dibacto Kemadjou
AU  - Boris Ronald Tchuente Tonou
AU  - Therese Henriette Dimodi
AU  - Gabriel Medoua Nama
AU  - Olga Yvonne Mankollo Bassong
Y1  - 2020/12/31
PY  - 2020
N1  - https://doi.org/10.11648/j.cajph.20200606.18
DO  - 10.11648/j.cajph.20200606.18
T2  - Central African Journal of Public Health
JF  - Central African Journal of Public Health
JO  - Central African Journal of Public Health
SP  - 365
EP  - 371
PB  - Science Publishing Group
SN  - 2575-5781
UR  - https://doi.org/10.11648/j.cajph.20200606.18
AB  - Background: Diabetes is a public health problem worldwide and in sub-Saharan African countries such as Cameroon. According to many studies, the use of antipsychotic drugs increases the risk of developing diabetes mellitus by 2 to 3 times more in people with psychotic disorders than in the general population. The present study aimed to assess the influence of antipsychotic drugs used on the risk of developing diabetes and to identify other factors predictive of abnormal blood glucose levels in patients suffering from psychosis. Methods: A cross-sectional study was conducted from the 3rd to the 19th of January 2018. Patients aged at least 18 years old suffering from psychosis and undiagnosed as diabetic before initiation of antipsychotic treatment were recruited at the Jamot Hospital in Yaoundé. A questionnaire was used to collect sociodemographic, anthropometric, and clinical data. The Chi-Square test was used to assess the relationship between hyperglycemia and categorical variables and the multivariate logistic regression model was used to determine independent predictors of hyperglycemia through the Statistical Package for the Social Sciences (SPSS) version 20.0. Results: A total of 82 patients were included in the study (41 males and 41 females). The fasting blood sugar ≥100 mg/dL appeared to be higher but not significant in patients on atypical antipsychotic therapy (124.74±23.31mg/dL) compared to patients on typical antipsychotic therapy (115.74±18.63 mg/dL); with a positive and non-significant correlation between hyperglycemia and duration of treatment (r=0.215; p=0.053). However, in both typical and atypical antipsychotic patients, fasting glucose sugar levels between 110-125mg/dL were observed at the same level (118.07±4.84 mg/dL and 118.09±3.41mg/dL respectively). Male sex (OR=1.41; 95% CI 0.54-3.64), age group < 35 years (OR=1.84; 95% CI 0.69-4.88), single (OR=2.18; 95% CI 0.83-5.67), typical antipsychotic drugs (OR=1.12; 95% CI 0.42-3.01), schizophrenia (OR=1.80; 95% CI 0.25-12.84) and bipolar disorder (OR=1.50; 95% CI 0.14-15.46) were independent predictors of hyperglycemia in those patients. Conclusion: Regular monitoring of anthropometric and clinical parameters should be assigned to people suffering from psychotic disorders and under treatment. Therefore, they should benefit from good management of the risk factors for diabetes to prevent the onset of the disease and avoid increased morbidity and mortality in this vulnerable population.
VL  - 6
IS  - 6
ER  -

Copy | Download

Author Information

Hermine Raissa Hell

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Maxwell Nguedjo Wandji

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Celine Sylvie Mimboe Bilongo

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Ruth Edwige Dibacto Kemadjou

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Boris Ronald Tchuente Tonou

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Therese Henriette Dimodi

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Gabriel Medoua Nama

Centre for Food and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, Yaounde, Cameroon
Olga Yvonne Mankollo Bassong

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Hermine Raissa Hell, Maxwell Nguedjo Wandji, Celine Sylvie Mimboe Bilongo, Ruth Edwige Dibacto Kemadjou, Boris Ronald Tchuente Tonou, et al. (2020). Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Central African Journal of Public Health, 6(6), 365-371. https://doi.org/10.11648/j.cajph.20200606.18

Copy | Download

ACS Style

Hermine Raissa Hell; Maxwell Nguedjo Wandji; Celine Sylvie Mimboe Bilongo; Ruth Edwige Dibacto Kemadjou; Boris Ronald Tchuente Tonou, et al. Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Cent. Afr. J. Public Health 2020, 6(6), 365-371. doi: 10.11648/j.cajph.20200606.18

Copy | Download

AMA Style

Hermine Raissa Hell, Maxwell Nguedjo Wandji, Celine Sylvie Mimboe Bilongo, Ruth Edwige Dibacto Kemadjou, Boris Ronald Tchuente Tonou, et al. Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study. Cent Afr J Public Health. 2020;6(6):365-371. doi: 10.11648/j.cajph.20200606.18

Copy | Download

@article{10.11648/j.cajph.20200606.18,
  author = {Hermine Raissa Hell and Maxwell Nguedjo Wandji and Celine Sylvie Mimboe Bilongo and Ruth Edwige Dibacto Kemadjou and Boris Ronald Tchuente Tonou and Therese Henriette Dimodi and Gabriel Medoua Nama and Olga Yvonne Mankollo Bassong},
  title = {Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study},
  journal = {Central African Journal of Public Health},
  volume = {6},
  number = {6},
  pages = {365-371},
  doi = {10.11648/j.cajph.20200606.18},
  url = {https://doi.org/10.11648/j.cajph.20200606.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20200606.18},
  abstract = {Background: Diabetes is a public health problem worldwide and in sub-Saharan African countries such as Cameroon. According to many studies, the use of antipsychotic drugs increases the risk of developing diabetes mellitus by 2 to 3 times more in people with psychotic disorders than in the general population. The present study aimed to assess the influence of antipsychotic drugs used on the risk of developing diabetes and to identify other factors predictive of abnormal blood glucose levels in patients suffering from psychosis. Methods: A cross-sectional study was conducted from the 3rd to the 19th of January 2018. Patients aged at least 18 years old suffering from psychosis and undiagnosed as diabetic before initiation of antipsychotic treatment were recruited at the Jamot Hospital in Yaoundé. A questionnaire was used to collect sociodemographic, anthropometric, and clinical data. The Chi-Square test was used to assess the relationship between hyperglycemia and categorical variables and the multivariate logistic regression model was used to determine independent predictors of hyperglycemia through the Statistical Package for the Social Sciences (SPSS) version 20.0. Results: A total of 82 patients were included in the study (41 males and 41 females). The fasting blood sugar ≥100 mg/dL appeared to be higher but not significant in patients on atypical antipsychotic therapy (124.74±23.31mg/dL) compared to patients on typical antipsychotic therapy (115.74±18.63 mg/dL); with a positive and non-significant correlation between hyperglycemia and duration of treatment (r=0.215; p=0.053). However, in both typical and atypical antipsychotic patients, fasting glucose sugar levels between 110-125mg/dL were observed at the same level (118.07±4.84 mg/dL and 118.09±3.41mg/dL respectively). Male sex (OR=1.41; 95% CI 0.54-3.64), age group < 35 years (OR=1.84; 95% CI 0.69-4.88), single (OR=2.18; 95% CI 0.83-5.67), typical antipsychotic drugs (OR=1.12; 95% CI 0.42-3.01), schizophrenia (OR=1.80; 95% CI 0.25-12.84) and bipolar disorder (OR=1.50; 95% CI 0.14-15.46) were independent predictors of hyperglycemia in those patients. Conclusion: Regular monitoring of anthropometric and clinical parameters should be assigned to people suffering from psychotic disorders and under treatment. Therefore, they should benefit from good management of the risk factors for diabetes to prevent the onset of the disease and avoid increased morbidity and mortality in this vulnerable population.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Risk of Diabetes in Cameroonian Patients with Psychosis and Under Antipsychotic Therapy: A Cross-Sectional Study
AU  - Hermine Raissa Hell
AU  - Maxwell Nguedjo Wandji
AU  - Celine Sylvie Mimboe Bilongo
AU  - Ruth Edwige Dibacto Kemadjou
AU  - Boris Ronald Tchuente Tonou
AU  - Therese Henriette Dimodi
AU  - Gabriel Medoua Nama
AU  - Olga Yvonne Mankollo Bassong
Y1  - 2020/12/31
PY  - 2020
N1  - https://doi.org/10.11648/j.cajph.20200606.18
DO  - 10.11648/j.cajph.20200606.18
T2  - Central African Journal of Public Health
JF  - Central African Journal of Public Health
JO  - Central African Journal of Public Health
SP  - 365
EP  - 371
PB  - Science Publishing Group
SN  - 2575-5781
UR  - https://doi.org/10.11648/j.cajph.20200606.18
AB  - Background: Diabetes is a public health problem worldwide and in sub-Saharan African countries such as Cameroon. According to many studies, the use of antipsychotic drugs increases the risk of developing diabetes mellitus by 2 to 3 times more in people with psychotic disorders than in the general population. The present study aimed to assess the influence of antipsychotic drugs used on the risk of developing diabetes and to identify other factors predictive of abnormal blood glucose levels in patients suffering from psychosis. Methods: A cross-sectional study was conducted from the 3rd to the 19th of January 2018. Patients aged at least 18 years old suffering from psychosis and undiagnosed as diabetic before initiation of antipsychotic treatment were recruited at the Jamot Hospital in Yaoundé. A questionnaire was used to collect sociodemographic, anthropometric, and clinical data. The Chi-Square test was used to assess the relationship between hyperglycemia and categorical variables and the multivariate logistic regression model was used to determine independent predictors of hyperglycemia through the Statistical Package for the Social Sciences (SPSS) version 20.0. Results: A total of 82 patients were included in the study (41 males and 41 females). The fasting blood sugar ≥100 mg/dL appeared to be higher but not significant in patients on atypical antipsychotic therapy (124.74±23.31mg/dL) compared to patients on typical antipsychotic therapy (115.74±18.63 mg/dL); with a positive and non-significant correlation between hyperglycemia and duration of treatment (r=0.215; p=0.053). However, in both typical and atypical antipsychotic patients, fasting glucose sugar levels between 110-125mg/dL were observed at the same level (118.07±4.84 mg/dL and 118.09±3.41mg/dL respectively). Male sex (OR=1.41; 95% CI 0.54-3.64), age group < 35 years (OR=1.84; 95% CI 0.69-4.88), single (OR=2.18; 95% CI 0.83-5.67), typical antipsychotic drugs (OR=1.12; 95% CI 0.42-3.01), schizophrenia (OR=1.80; 95% CI 0.25-12.84) and bipolar disorder (OR=1.50; 95% CI 0.14-15.46) were independent predictors of hyperglycemia in those patients. Conclusion: Regular monitoring of anthropometric and clinical parameters should be assigned to people suffering from psychotic disorders and under treatment. Therefore, they should benefit from good management of the risk factors for diabetes to prevent the onset of the disease and avoid increased morbidity and mortality in this vulnerable population.
VL  - 6
IS  - 6
ER  -

Copy | Download